SHANK3 HaploinsufficiencyPhase 1RB001-101-LTFUNCT07690527
Long-Term Follow-Up Study for RB001 Gene Therapy Study in Children With SHANK3-related Phelan McDermid Syndrome (PMS)
A Phase 1 study testing RB001 in people with SHANK3 Haploinsufficiency and Phelan-McDermid Syndrome, run by Peking University First Hospital at 1 site in China.
Trial summary
This is a long-term follow-up study of participants in the RB001-101 gene replacement therapy clinical trial for Children With SHANK3-related Phelan-McDermid Syndrome (PMS). Participants will roll over from the parent study into this long-term study for continuous safety monitoring and preliminary efficacy assessment… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- SHANK3 Haploinsufficiency, Phelan-McDermid Syndrome
- What is being tested?
- RB001
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 8 participants
- Where
- 1 siteChina
- Study dates
- 1 Aug 2026to 1 Dec 2031
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Patients with SHANK3-related Phelan-McDermid Syndrome who have completed the last follow-up visit (Week 52 post-dosing) in the RB001-101 study.
Who cannot join
- Some conditions deemed unsuitable for participation in this study by the investigator
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: A Long-term Follow-up Study of an Open-label, Single-arm, Single-dose Escalation Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intracerebroventricular Injection of RB001 in Participants With SHANK3-related Phelan-McDermid Syndrome.
This is a long-term follow-up study of participants in the RB001-101 gene replacement therapy clinical trial for Children With SHANK3-related Phelan-McDermid Syndrome (PMS). Participants will roll over from the parent study into this long-term study for continuous safety monitoring and preliminary efficacy assessment for up to 5 years.
Read the detailed description
RB001 is an adeno-associated virus (AAV) based gene therapy product. In the preceding RB001-101 clinical study (NCT07014020), 8 participants have been dosed. To date, no serious adverse events have been observed in any participant, and preliminary improvements were noted. In accordance with guidelines for gene therapy products and pediatric rare diseases, long-term follow-up is mandatory to monitor delayed adverse events, assess durability of efficacy, and evaluate long-term developmental benefits. Therefore, we designed this long-term follow-up (LTFU) study, which will roll over participants from the parent study to continuously track the long-term risks and benefits of RB001, providing critical long-term evidence for clinical application.
This is a long-term, safety and preliminary efficacy follow-up study of participants in the RB001-101 gene replacement therapy clinical trial for children with SHANK3-related Phelan-McDermid Syndrome (PMS), delivering RB001 via intracerebroventricular injection. Participants will roll over from the parent study into this long-term study for continuous safety and preliminary efficacy monitoring for a total of 5 years. The last visit of the parent study or early discontinuation from the parent study will serve as the visit at which the informed consent form process is conducted for this long-term follow-up study. Participants will return to the research center for follow-up visits every six months for 5 years (after RB001 administration). Additionally, patient record transfers from their local physician and/or neurologist will be requested in conjunction with these study visits for review by the investigator. If the patient is unable to return to the original investigative site, the sponsor will arrange with the patient's local established physician to serve as an additional investigator to conduct the required assessments.
- Being tested
- RB001
- Keywords
- AAV, SHANK3, Phelan-McDermid Syndrome, Gene therapy, 22q13.3 deletion syndrome
- Medical subject headings
- Telomeric 22q13 Monosomy Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RB001Biological
The study enrolled up to 2 cohorts, evaluating a higher or lower dose
| Study group | Role | What they receive |
|---|---|---|
| RB001 | Experimental | RB001 interaventricular administration; the duration of the study is 1 to 5 years follow-up visit period. Receives: Biological: RB001 |
What is being measured
The primary outcome is the main question the study is designed to answer.
To evaluate the safety and tolerability of a single intracerebroventricular injection of RB001
Types, severity, and incidence of adverse events (AEs) and serious adverse events (SAEs)
Measured: 1 to 5 years
Secondary outcomes (13)
To evaluate the changes on Clinical Global Impression Scale - Severity (CGI-S) after a single intracerebroventricular injection of RB001
Clinical Global Impression Scale (CGI) severity item provided with a seven-point scale of severity of patient's clinical condition (1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients.)
Measured: 1 to 5 years
To evaluate the changes on Clinical Global Impression Scale - Improvement (CGI-I) after a single intracerebroventricular injection of RB001
Clinical Global Impression Scale (CGI) Improvement item provided with a seven-point scale of improvement of patient's clinical condition (1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment.)
Measured: 1 to 5 years
To evaluate the changes on Patient's Global Impressions of Improvement (PGI-I) after a single intracerebroventricular injection of RB001
The PGI-I consists of a single item in which participants or their parents rate the participant's overall health status relative to baseline using a 7 point scale, scale anchors correspond to those of the CGI-I: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse
Measured: 1 to 5 years
To evaluate the changes on Childhood Autism Rating Scale (CARS-2) after a single intracerebroventricular injection of RB001
The CARS2 is a clinician completed rating scale based on direct observation of the child's behavior in standardized contexts. It comprises 15 descriptive items assessing domains including relating to people, imitation, emotional response, body use, object use, and adaptation to change. Each item is scored from 0 to 4, with 0 indicating no abnormality and 4 indicating severe abnormality. The rater integrates behavioral observations with an overall clinical impression of severity to compute a total score ranging from 15 to 60, and converted into a T-score through norm-referenced comparison. Higher T-scores indicate a higher level of autism severity, and a T-score >40 indicates the presence of moderate or above autism related symptoms.
Measured: 1 to 5 years
To evaluate the changes on Autism Behavior Checklist (ABC) after a single intracerebroventricular injection of RB001
The ABC is a clinician rated instrument based on direct observation of the child's behavior. It includes 57 items distributed across five domains: sensory, relating, body and object use, language, and self#help behavior. Each item is rated as either "yes" (present) or "no" (absent), based on whether the behavior is observed. The total score is calculated by summing the weighted scores of items endorsed as "yes" (item weights vary from 1 to 4). Higher total scores indicate greater autism#related behavioral impairment. The score is interpreted as follows: total < 53 = negative (low risk), 53-67 = suspicious (moderate risk), and ≥ 68 = positive (high clinical concern for autism spectrum disorder).
Measured: 1 to 5 years
To evaluate the changes on Griffith developmental assessment scale - Chinese (GDS-C) after a single intracerebroventricular injection of RB001
the Griffiths Developmental Assessment Scale - Chinese Version (GDS-C) is accessed by certified examiners. The scale evaluates 240 age-standardized tasks across six domains (Locomotor, Personal-Social, Language, Eye-Hand Coordination, Performance, and Practical Reasoning). Tasks are scored 0 or 1 (1=pass, 0=fail), with raw scores converted to Developmental Quotients (DQ) using China-specific norms (2020 revision). DQ<85 suggests potential mild developmental delay, while a multi-domain DQ<70 indicates significant developmental delay.
Measured: 1 to 5 years
To evaluate the changes on Peabody developmental motor scales - 2nd Edition (PDMS-2) after a single intracerebroventricular injection of RB001
The PDMS-2 is a standardized, norm#referenced clinical tool used to assess gross and fine motor development in children. Certified clinicians administer age appropriate items across five domains: reflexes, stationary, locomotion, grasping, and object manipulation. each item is scored based on the child's level of performance, and raw scores are converted to standard scores, percentiles, and composite motor quotients including the gross motor quotient, fine motor quotient, and total motor quotient. Motor quotients are norm#referenced with a mean of 100 and standard deviation of 15. A motor quotient < 85 indicates potential mild motor delay, while a quotient < 70 suggests significant motor developmental impairment.
Measured: 1 to 5 years
To evaluate the changes on Wechsler Preschool and Primary Scale of Intelligence (WPPSI) or Wechsler Intelligence Scale for Children (WISC) after a single intracerebroventricular injection of RB001
the certified neuropsychologist conducts assessments under standardized conditions and assigns scores based on five scales (Verbal Comprehension, Visual Spatial, Fluid/Quantitative Reasoning, Working Memory, Processing Speed) to derive a Full Scale IQ. Scores are norm-referenced (mean=100, SD=15), with higher values indicating superior cognitive ability. IQ<85 suggests potential mild cognitive delay, while IQ<70 indicates significant cognitive delay.
Measured: 1 to 5 years
To evaluate the changes on Adaptive Behavior Assessment System-Second Edition (ABAS-2) after a single intracerebroventricular injection of RB001
To evaluate changes of functional adaptive behaviors from baseline at weeks 12, 26, and 52 after RB001 injection, the Adaptive Behavior Assessment System-Second Edition (ABAS-2) is administered. the rater (usually the Guardian) score the child's daily living skills across 10 domains (Communication, Self-Care, Social, etc.) using age-specific questionnaires. Items are scored 0-3 based on frequency of competent performance, and raw scores normalized to standard scores based on ages (mean=100, SD=15). The General Adaptive Composite (GAC) serves as the primary secondary endpoint. CAG < 85 suggests potential mild delay, while CAG ≤ 70 indicates significant delay.
Measured: 1 to 5 years
To evaluate the changes on Social Life Ability Scale For Infant-Junior Middle School Student (S-M) after a single intracerebroventricular injection of RB001
To evaluate adaptive functioning from baseline at weeks 12, 26, and 52 after RB001 injection, the Social Life Ability Scale for Infants-Junior Middle School Students (S-M Scale) is administered. Parents or primary caregivers observe the child's daily behaviors and score 132 specific items across six functional domains (Independent Living Skills, Motor Abilities, Practical Task Performance, Communication Skills, Self-Management, and Socialization). Each item is scored 0 or 1 (1 = pass, 0 = fail) based on observed capability. The total score (0-132) is calculated by summing all items, with higher scores indicating better adaptive functioning. A standard score ≤9 (equivalent to a raw score ≤70; ≥2 SD below the norm) suggests significant impairment in social adaptive abilities.
Measured: 1 to 5 years
To evaluate the changes on Child Behavior Checklist (CBCL) after a single intracerebroventricular injection of RB001
To evaluate behavioral/emotional problems from baseline at weeks 12, 26, and 52 after RB001 injection, the Child Behavior Checklist (CBCL) is administered. Parents or caregivers rate the child's behaviors using 113+ problem items across empirically based syndromes (Anxious/Depressed, Withdrawn/Depressed, Somatic Complaints, Social Problems, Thought Problems, Attention Problems, Rule-Breaking Behavior, and Aggressive Behavior). Each item is scored 0-2 (0 = not true, 1 = sometimes true, 2 = very/often true). The total problem score (0-240) is calculated by summing all items, with higher scores indicating greater behavioral/emotional impairment. A T-score >63 (>90th percentile) suggests clinical concern, and >70 (>98th percentile) indicates. (T-scores (M = 50, SD = 10) are derived from normative samples).
Measured: 1 to 5 years
To evaluate the changes on Children's sleep habits questionnaire(CSHQ) after a single intracerebroventricular injection of RB001
The CSHQ is a validated parent report screening tool used to assess sleep patterns and common sleep disturbances in children. Parents or primary caregivers rate their child's recent sleep behaviors across multiple domains, including bedtime resistance, sleep onset latency, sleep duration, night wakings, sleep anxiety, parasomnias, sleep disordered breathing, and daytime sleepiness. The questionnaire consists of 45 items, each scored on a frequency scale based on how often the behavior occurred during the past week: 1 = frequently (5-7 times), 2 = sometimes (2-4 times), and 3 = rarely (0-1 times). The total score is computed using the established scoring criteria; higher score indicate more severe sleep problems.
Measured: 1 to 5 years
To evaluate AAV neutralizing antibodies after a single intracerebroventricular injection of RB001
To evaluate AAV neutralizing antibodies (Abs) titer after RB001 injection. blood samples will be collected at each time point. Antibodies will be quantified using cell-coculture method.
Measured: 1 to 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jul 2026
- Study start1 Aug 2026 (estimated)
- Primary completion1 Jul 2031 (estimated)
- Study completion1 Dec 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SHANK3 HaploinsufficiencyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Single group assignment: an open-label, single arm, dose-escalation clinical study to evaluating the long-term safety, tolerability and preliminary efficacy of a single intracerebroventricular Injection of RB001
- Masking
- None (open label)
- Enrolment
- 8 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Peking University First Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Shenzhen Reborngene Therapeutics Co., Ltd.
- Responsible party
- Principal investigator, Ye Wu, Peking University First Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07690527
- Sponsor's protocol ID
- RB001-101-LTFU
- Other IDs
- 2026R0416-0001
- Acronym
- RB001-101-LTFU
- Status last verified
- Jul 2026
- First submitted
- 1 Jul 2026
- Last updated
- 13 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Long-term Follow-up Study of an Open-label, Single-arm, Single-dose Escalation Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intracerebroventricular Injection of RB001 in Participants With SHANK3-related Phelan-McDermid Syndrome.
- ClinicalTrials.gov ID
- NCT07690527
- Acronym / sponsor ID
- RB001-101-LTFU / RB001-101-LTFU
- Keywords
- AAV, SHANK3, Phelan-McDermid Syndrome, Gene therapy, 22q13.3 deletion syndrome
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 8 participants (estimated)
- Lead sponsor
- Peking University First HospitalUniversity, hospital or other
- Collaborators
- Shenzhen Reborngene Therapeutics Co., Ltd.
- Study start
- 1 Aug 2026 (estimated)
- Primary completion
- 1 Jul 2031 (estimated)
- Study completion
- 1 Dec 2031 (estimated)
- First posted
- 8 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a long-term follow-up study of participants in the RB001-101 gene replacement therapy clinical trial for Children With SHANK3-related Phelan-McDermid Syndrome (PMS). Participants will roll over from the parent study into this long-term study for continuous safety monitoring and preliminary efficacy assessment for up to 5 years.
Detailed description
RB001 is an adeno-associated virus (AAV) based gene therapy product. In the preceding RB001-101 clinical study (NCT07014020), 8 participants have been dosed. To date, no serious adverse events have been observed in any participant, and preliminary improvements were noted. In accordance with guidelines for gene therapy products and pediatric rare diseases, long-term follow-up is mandatory to monitor delayed adverse events, assess durability of efficacy, and evaluate long-term developmental benefits. Therefore, we designed this long-term follow-up (LTFU) study, which will roll over participants from the parent study to continuously track the long-term risks and benefits of RB001, providing critical long-term evidence for clinical application.
This is a long-term, safety and preliminary efficacy follow-up study of participants in the RB001-101 gene replacement therapy clinical trial for children with SHANK3-related Phelan-McDermid Syndrome (PMS), delivering RB001 via intracerebroventricular injection. Participants will roll over from the parent study into this long-term study for continuous safety and preliminary efficacy monitoring for a total of 5 years. The last visit of the parent study or early discontinuation from the parent study will serve as the visit at which the informed consent form process is conducted for this long-term follow-up study. Participants will return to the research center for follow-up visits every six months for 5 years (after RB001 administration). Additionally, patient record transfers from their local physician and/or neurologist will be requested in conjunction with these study visits for review by the investigator. If the patient is unable to return to the original investigative site, the sponsor will arrange with the patient's local established physician to serve as an additional investigator to conduct the required assessments.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Single group assignment: an open-label, single arm, dose-escalation clinical study to evaluating the long-term safety, tolerability and preliminary efficacy of a single intracerebroventricular Injection of RB001
| Arm | Type | Receives |
|---|---|---|
| RB001 | Experimental | Biological: RB001RB001 interaventricular administration; the duration of the study is 1 to 5 years follow-up visit period. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- Patients with SHANK3-related Phelan-McDermid Syndrome who have completed the last follow-up visit (Week 52 post-dosing) in the RB001-101 study.
Key exclusion criteria (1 listed)
- Some conditions deemed unsuitable for participation in this study by the investigator
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RB001The study enrolled up to 2 cohorts, evaluating a higher or lower dose | Biological | RB001 |
Primary outcome
To evaluate the safety and tolerability of a single intracerebroventricular injection of RB001
Time frame: 1 to 5 years
Types, severity, and incidence of adverse events (AEs) and serious adverse events (SAEs)
13 secondary outcomes
To evaluate the changes on Clinical Global Impression Scale - Severity (CGI-S) after a single intracerebroventricular injection of RB001
Time frame: 1 to 5 years
To evaluate the changes on Clinical Global Impression Scale - Improvement (CGI-I) after a single intracerebroventricular injection of RB001
Time frame: 1 to 5 years
To evaluate the changes on Patient's Global Impressions of Improvement (PGI-I) after a single intracerebroventricular injection of RB001
Time frame: 1 to 5 years
To evaluate the changes on Childhood Autism Rating Scale (CARS-2) after a single intracerebroventricular injection of RB001
Time frame: 1 to 5 years
To evaluate the changes on Autism Behavior Checklist (ABC) after a single intracerebroventricular injection of RB001
Time frame: 1 to 5 years
To evaluate the changes on Griffith developmental assessment scale - Chinese (GDS-C) after a single intracerebroventricular injection of RB001
Time frame: 1 to 5 years
To evaluate the changes on Peabody developmental motor scales - 2nd Edition (PDMS-2) after a single intracerebroventricular injection of RB001
Time frame: 1 to 5 years
To evaluate the changes on Wechsler Preschool and Primary Scale of Intelligence (WPPSI) or Wechsler Intelligence Scale for Children (WISC) after a single intracerebroventricular injection of RB001
Time frame: 1 to 5 years
To evaluate the changes on Adaptive Behavior Assessment System-Second Edition (ABAS-2) after a single intracerebroventricular injection of RB001
Time frame: 1 to 5 years
To evaluate the changes on Social Life Ability Scale For Infant-Junior Middle School Student (S-M) after a single intracerebroventricular injection of RB001
Time frame: 1 to 5 years
To evaluate the changes on Child Behavior Checklist (CBCL) after a single intracerebroventricular injection of RB001
Time frame: 1 to 5 years
To evaluate the changes on Children's sleep habits questionnaire(CSHQ) after a single intracerebroventricular injection of RB001
Time frame: 1 to 5 years
To evaluate AAV neutralizing antibodies after a single intracerebroventricular injection of RB001
Time frame: 1 to 5 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jul 2026.
- RB001-101(NCT07014020)Link provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for SHANK3 Haploinsufficiency
RecruitingPhase 1/2
JAG201 Gene Therapy Study in Children & Adults With SHANK3 Haploinsufficiency
SHANK3 Haploinsufficiency, Phelan-McDermid Syndrome
Active, not recruitingPhase 1
RB001 Gene Therapy Study in Children With SHANK3-related Phelan-McDermid Syndrome (PMS)
Phelan-McDermid Syndrome, SHANK3 Haploinsufficiency
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing RB001 in people with SHANK3 Haploinsufficiency and Phelan-McDermid Syndrome, run by Peking University First Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 13 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To evaluate the safety and tolerability of a single intracerebroventricular injection of RB001 (time frame: 1 to 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jul 2026.